Timothy Chan, MD, PhD
Director, Center for Immunotherapy & Precision Immuno-Oncology
Lerner Research Institute,
9500 Euclid Avenue, Cleveland, Ohio 44195
Timothy Chan, MD, PhD, a renowned immuno-oncology and cancer genomics expert, leads the Center for Immunotherapy and Precision Immuno-Oncology, which brings together multidisciplinary experts from across the Cleveland Clinic enterprise to advance research and treatment related to the rapidly growing field of immuno-oncology.
Dr. Chan also collaborates with experts in the Center for Global and Emerging Pathogens Research, which is focused on broadening understanding of immunology and microbial pathogenesis with the goal of improving treatment for a variety of diseases, including virus-induced cancers.
He is an internationally recognized expert in precision immuno-oncology and a pioneer in using genomics to determine which patients will respond best to certain types of immunotherapies. He has published over 200 articles in peer-reviewed journals, made landmark discoveries in his field and received numerous awards, including the National Cancer Institute Outstanding Investigator Award in 2018.
Dr. Chan earned his MD and PhD in genetics from Johns Hopkins University, where he also completed a residency in radiation oncology and a postdoctoral fellowship in the division of tumor biology. He is board certified in radiation oncology and is an elected member of the Association of American Physicians.
The focus of the Chan laboratory is to understand the genomic basis of tumor development and treatment response. We use both large-scale genomic analyses and functional dissection to determine what drives oncogenesis. From this information, we seek to develop improved diagnostic and therapeutic modalities for human cancers.
Learn more on the Chan Lab webpage
Cleveland Clinic has been named as one of four institutions of a new consortium grant from the Aligning Science Across Parkinson’s (ASAP) initiative to investigate the association between Parkinson’s disease and immunity. The multi-site consortium will be led by researchers at Massachusetts General Hospital / Harvard Medical School and also includes those from the University of Houston and MD Anderson Cancer Center at the University of Texas.
VIDEO: New Center for Immunotherapy and Precision Immuno-Oncology to Help Advance Head and Neck Cancer Research
With one of the largest cell production facilities in the state and a robust biorepository, Cleveland Clinic aims to lead the future of head and neck cancer and cancer therapies, including immunotherapies. Cleveland Clinic has made a strong commitment—over $80 million—to fund its new Center for Immunotherapy and Precision Immuno-Oncology (CITI), which will support immunotherapy research and care related to many types of cancers. Hear from Brian Burkey, MD, vice chair of the Head & Neck Institute, and Timothy Chan, MD, PhD, director of CITI, about how the two teams will work together to advance head and neck cancer translational research, with the ultimate goal to enhance patient care and outcomes.